Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAZITHROMYCIN (azithromycin monohydrate) by Fresenius Kabi is clinical pharmacology pharmacokinetics in patients hospitalized with community-acquired pneumonia receiving single daily one-hour intravenous infusions for 2 to 5 days of 500 mg azithromycin at a concentration of 2 mg/ml, the mean c max ± s. First approved in 2005.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Pharmacokinetics In patients hospitalized with community-acquired pneumonia receiving single daily one-hour intravenous infusions for 2 to 5 days of 500 mg azithromycin at a concentration of 2 mg/mL, the mean C max ± S.D. achieved was 3.63 ± 1.6 mcg/mL, while the 24-hour…
Worked on AZITHROMYCIN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
Azithromycin Before Induction
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo